Patents by Inventor Ronald Cornelis Marie KALMEIJER

Ronald Cornelis Marie KALMEIJER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION
    Publication number: 20210403908
    Abstract: Described are RNA interference (RNAi) agents for treating a Hepatitis D Virus (HDV) infection in a subject in need thereof.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 30, 2021
    Inventors: Ronald Cornelis Marie Kalmeijer, Michael Biermer, Oliver Lenz, Maria Gloria Beumont, Heather Lynn Davis, Thomas Naoki Kakuda
  • RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION
    Publication number: 20210395745
    Abstract: Described are methods for inhibition of Hepatitis B virus gene expression or treating symptoms and/or diseases associated with Hepatitis B virus infection. Dosing regimens for administering these RNAi agents are also described. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.
    Type: Application
    Filed: August 6, 2021
    Publication date: December 23, 2021
    Applicants: Arrowhead Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc.
    Inventors: Bruce D. GIVEN, James C. HAMILTON, Thomas SCHLUEP, Maria Gloria BEUMONT, Oliver LENZ, Ronald Cornelis Marie KALMEIJER
  • COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION
    Publication number: 20210285000
    Abstract: Described are RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B Virus (HBV) used in combination with a capsid assembly modulator (CAM) and an interferon, and methods of administering same. The HBV RNAi agents, CAMs and interferon are administered to effectively inhibit HBV gene expression and to treat diseases and conditions associated with HBV infection, particularly in immune tolerant subjects.
    Type: Application
    Filed: March 4, 2021
    Publication date: September 16, 2021
    Inventors: Ronald Cornelis Marie KALMEIJER, Michael BIERMER, Oliver LENZ, Heather Lynn DAVIS, Cristiana MAYER